Nicardipine is a calcium channel blocker used for the short-term treatment of hypertension and chronic stable angina. A potent calcium channel blockader with marked vasodilator action.
- Mechanism
- Curator reviewed
By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, nicardipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
- Primary indication
- Used for the management of patients with chronic stable angina and for the treatment of hypertension.Curator reviewed · 5 structured indications
- Formula / weight
- C26H29N3O6 · 479.525 g/mol (avg)
- First approval
- Canada, 1990 · United States, 1992
- Brand names
Resolves to
ZBBHBTPTTSWHBA-UHFFFAOYSA-NSMILESCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Nicardipine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account